About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The work of our group is mainly focused on personalized medicine, including chemical-functional stability studies of drugs in individualized preparations to be administered both orally and parenterally, as well as parenteral nutrition; research focused on the evaluation and/or design of population pharmacokinetic/pharmacodynamic (PK/PD) models and the characterization of the pharmacokinetics of certain drugs of therapeutic interest in the general population or in certain population groups; and research focused on pharmacogenetics and pharmacogenomics. Our research is also focused on advanced interventions: drug evaluation studies (effectiveness, safety and economic studies); and mobile health and telepharmacy.
PMID: 34546485 Journal: European Journal of Health Economics Year: 2022 Reference: Eur J Health Econ. 2022 Apr;23(3):551-558. doi: 10.1007/s10198-021-01378-x. Epub 2021 Sep 21. Impact factor: Publication type: Paper in international publication Authors: Alsina, Laia; Casado, Miguel Angel; Gonzalez-Granado, Luis Ignacio; Montoro, J Bruno; Moral, Pedro Moral; Neth, Olaf; Oyaguez, Itziar; Pica, Marta Ortiz; Presa, Maria; Sanchez-Ramon, Silvia et al. DOI: 10.1007/s10198-021-01378-x
PMID: 34331263 Journal: INFECTION Year: 2022 Reference: Infection. 2022 Apr;50(2):371-380. doi: 10.1007/s15010-021-01662-1. Epub 2021 Jul 30. Impact factor: Publication type: Paper in international publication Authors: Almirante, Benito; Campos-Varela, Isabel; Clofent, David; Eremiev, Simeon; Falco-Roget, Anna; Garcia-Garcia, Sonia; Kirkegaard, Cristina; Leguizamo, Lina Maria; Len, Oscar; Marzo, Blanca et al. DOI: 10.1007/s15010-021-01662-1
PMID: 35171022 Journal: Microbiology Spectrum Year: 2022 Reference: Microbiol Spectr. 2022 Feb 23;10(1):e0178421. doi: 10.1128/spectrum.01784-21. Epub 2022 Feb 16. Impact factor: Publication type: Paper in international publication Authors: Berastegui, Cristina; Bravo, Carles; Campany-Herrero, David; Castells, Lluis; Deu, Maria; Gavalda, Joan; Len, Oscar; Los-Arcos, Ibai; Marquez-Algaba, Ester; Martin-Gomez, Maria Teresa et al. DOI: 10.1128/spectrum.01784-21
PMID: 36704126 Journal: Frontiers in Pediatrics Year: 2022 Reference: Front Pediatr. 2023 Jan 10;10:1099305. doi: 10.3389/fped.2022.1099305. eCollection 2022. Impact factor: Publication type: Letter whit IF Authors: Cabanas Poy, Maria Jose; Frick, Marie Antoinette; Hernandez-Perez, Susana; Parramon-Teixido, Carlos Javier; Puertas Sanjuan, Adrian et al. DOI: 10.3389/fped.2022.1099305
PMID: 33429950 Journal: Pharmaceutics Year: 2021 Reference: Pharmaceutics. 2021 Jan 8;13(1). pii: pharmaceutics13010077. doi: 10.3390/pharmaceutics13010077. Impact factor: Publication type: Paper in international publication Authors: Alvarez, Rebeca; Blanca-Garcia, Jose A; Bossacoma, Ferran; Clemente, Susana; Dopazo, Ana; Eizaguirre, Francisco J; Fobelo, Maria J; Gallego-Fernandez, Carmen; Garcia-Romero, Ruth; Gonzalez de Caldas, Rafael et al. DOI: 10.3390/pharmaceutics13010077
PMID: 33426389 Journal: Kidney International Reports Year: 2021 Reference: Kidney Int Rep. 2020 Oct 12;6(1):101-109. doi: 10.1016/j.ekir.2020.09.046. eCollection 2021 Jan. Impact factor: Publication type: Paper in international publication Authors: Jatem, Elias; Lima, Joan; Montoro, Bruno; Segarra, Alfons; Torres-Bondia, Francisco et al. DOI: 10.1016/j.ekir.2020.09.046
PMID: 33095928 Journal: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS Year: 2021 Reference: J Clin Pharm Ther. 2021 Feb;46(1):50-65. doi: 10.1111/jcpt.13292. Epub 2020 Oct 23. Impact factor: Publication type: Review in international publication Authors: Francesc, Salva; Maria, Roca; Marta, Miarons et al. DOI: 10.1111/jcpt.13292
PMID: 32941394 Journal: TRANSPLANTATION Year: 2021 Reference: Transplantation. 2021 Jan 1;105(1):138-150. doi: 10.1097/TP.0000000000003460. Impact factor: Publication type: Paper in international publication Authors: Alonso-Martinez, Carla; Anton, Andres; Berastegui, Cristina; Castells, Lluis; Del-Rio-Gutierrez, Jose-Manuel; Domenech, Laura; Garcia-Garcia, Sonia; Garcia-Ortega, Patricia; Gomez-Ganda, Laura; Gorgas-Torner, Maria-Queralt et al. DOI: 10.1097/TP.0000000000003460
Within the framework of a clinical trial, the first 3D printed medicine in Europe in the pediatric field will be tested.
